Back on the Books Initiative Launched to Aid in Rescheduling Cancer Screening Appointments

News
Video

The goal of the initiative is to have cancer screenings that were made in the first half of 2020 and cancelled due to COVID-19 rescheduled to ensure patients are again receiving routine screenings.

The Prevent Cancer Foundation – the only US-based nonprofit organization solely dedicated to cancer prevention and early detection – has launched a new initiative titled, “Back on the Books.”

The goal of the initiative is to have any mammogram, Pap test, colonoscopy, PSA test, lung cancer screening, skin check, or dental appointment that was made during the first half of 2020 and cancelled due to the coronavirus disease 2019 (COVID-19) pandemic rescheduled by patients.

However, the leaders of the initiative also stressed that screening guidelines are never one-size-fits-all, especially during a pandemic. Therefore, patients should consult with their physician and make the best decision for themselves.

“When deciding when to get your routine screening back on the books, you should weigh the potential risk of exposure to the coronavirus against the potential risk of a late or missed cancer diagnosis,” the authors of the initiative wrote. “If you are immunocompromised or at high risk of complications from contracting the virus, it may make sense to wait. Call your health care provider for guidance.”

In an interview with CancerNetwork®, Lisa Berry Edwards, managing editor of external affairs for the Prevent Cancer Foundation, discussed the “Back on the Books” initiative and what patients should be aware of in regard to rescheduling their previously missed cancer screening appointments.

Reference:

Prevent Cancer Foundation. Back on the Books. Prevent Cancer Foundation Website. Published 2020. preventcancer.org/education/back-on-the-books/. Accessed July 30, 2020.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content